Global

Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.

Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.

The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.

Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.

Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.

The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.

The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.

The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.

CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

The combination met its primary end point in the phase 3 SANOVO trial, though full efficacy and safety data have not yet been reported.

The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.

The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.

Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.

Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.

The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1–positive, metastatic triple-negative breast cancer.

The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.

The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Amol Akhade, MD, discusses how biosimilars, subcutaneous formulations, and dose optimization each bear on the cost of cancer care.

Amol Akhade, MD, discusses the pharmacologic rationale for reduced-dose checkpoint inhibition and the funding barrier to definitive randomized evidence.

Amol Akhade, MD, discusses how cost shapes immunotherapy decisions and what standard cost-effectiveness measures miss for individual patients.

The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,